A selective ATP-binding cassette subfamily G member 2 efflux inhibitor revealed via high-throughput flow cytometry

Journal of Biomolecular Screening

Volumn 18, Issue 1, 2013, Pages 26-38

  Strouse, J Jacob ^a,b   Ivnitski Steele, Irena ^a,b   Khawaja, Hadya M ^a   Perez, Dominique ^a,b   Ricci, Jerec ^a   Yao, Tuanli ^c   Weiner, Warren S ^c   Schroeder, Chad E ^c   Simpson, Denise S ^c   Maki, Brooks E ^c   Li, Kelin ^c   Golden, Jennifer E ^c   Foutz, Terry D ^a,b   Waller, Anna ^a,b   Evangelisti, Annette M ^a,b   Young, Susan M ^a,b   Chavez, Stephanie E ^a,b   Garcia, Matthew J ^a,b   Ursu, Oleg ^b,d   Bologa, Cristian G ^b,d   Carter, Mark B ^a,b   Salas, Virginia M ^a,b   Gouveia, Kristine ^a,b   Tegos, George P ^a,b,e   Oprea, Tudor I ^b,d   Edwards, Bruce S ^a,b   Aubé, Jeffrey ^c   Larson, Richard S ^a   Sklar, Larry A ^a,b   more..

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c UNIVERSITY OF KANSAS   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

ABC transporter; ABCB1; ABCG2; efflux inhibition; multidrug resistance

Indexed keywords

ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CID 1434724; CID 1441553; CID 44602405; CID 44602407; CID 44607585; CID 44607976; CID 44623842; CID 44623844; CID 44629740; CID 44629742; CID 44630538; CID 44630540; CID 44630541; CID 44631078; CID 44640177; CID 44640182; CID 44640183; CID 45105073; CID 45105074; CID 45105075; CID 45105078; CID 45105080; CID 45105082; CID 45281172; CID 5105081; CID 644556; CID 652994; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DRUG BINDING; DRUG IDENTIFICATION; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, SCID; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PYRAZOLES; PYRIMIDINES; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84871590620     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057112456875     Document Type: Article

References (33)

1. Sarkadi B., Homolya L., Szakacs G., Varadi A.. Human Multidrug Resistance ABCB and ABCG Transporters: Participation in a Chemoimmunity Defense System. Physiol. Rev. 2006 ; 86: 1179-1236
2. Krishna R., Mayer L. D.. Multidrug Resistance (MDR) in Cancer: Mechanisms, Reversal Using Modulators of MDR and the Role of MDR Modulators in Influencing the Pharmacokinetics of Anticancer Drugs. Eur. J. Pharm. Sci. 2000 ; 11: 265-283
3. Gillet J.-P., Efferth T., Remacle J.. Chemotherapy-Induced Resistance by ATP-Binding Cassette Transporter Genes. Biochim. Biophys. Acta. 2007 ; 1775: 237-262
4. Szakacs G., Varadi A., Ozvegy-Laczka C., Sarkadi B.. The Role of ABC Transporters in Drug Absorption, Distribution, Metabolism, Excretion and Toxicity (ADME-Tox). Drug Discov. Today. 2008 ; 13: 379-393
5. Eckford P. D. W., Sharom F. J.. ABC Efflux Pump-Based Resistance to Chemotherapy Drugs. Chem. Rev. 2009 ; 109: 2989-3011
6. Atadja P., Watanabe T., Xu H., Cohen D.. PSC-833, a Frontier in Modulation of P-glycoprotein Mediated Multidrug Resistance. Cancer Metastasis Rev. 1998 ; 17: 163-168
7. Germann U. A., Shlyakhter D., Mason V. S., Zelle R. E., Duffy J. P., Galullo V., Armistead D. M., Saunders J. O., Boger J., Harding M. W.. Cellular and Biochemical Characterization of VX-710 as a Chemosensitizer: Reversal of P-glycoprotein-Mediated Multidrug Resistance In Vitro. Anti-Cancer Drugs. 1997 ; 8: 125-140
8. Dale I. L., Tuffley W., Callaghan R., Holmes J. A., Martin K., Luscombe M., Mistry P., Ryder H., Stewart A. J., Charlton P., et al. Reversal of P-glycoprotein-Mediated Multidrug Resistance by XR9051, a Novel Diketopiperazine Derivative. Br. J. Cancer. 1998 ; 78: 885-892
9. Mistry P., Stewart A. J., Dangerfield W., Okiji S., Liddle C., Bootle D., Plumb J. A., Templeton D., Charlton P.. In Vitro and In Vivo Reversal of P-glycoprotein-Mediated Multidrug Resistance by a Novel Potent Modulator, XR9576. Cancer Res. 2001 ; 61: 749-758
10. Stewart A., Steiner J., Mellows G., Laguda B., Norris D., Bevan P.. Phase I Trial of XR9576 in Healthy Volunteers Demonstrates Modulation of P-glycoprotein in CD56+ Lymphocytes after Oral and Intravenous Administration. Clin. Cancer Res. 2000 ; 6: 4186-4191
11. Jekerle V., Klinkhammer W., Scollard D. A., Breitbach K., Reilly R. M., Piquette-Miller M., Wiese M.. In Vitro and In Vivo Evaluation of WK-X-34, a Novel Inhibitor of P-glycoprotein and BCRP, Using Radio Imaging Techniques. Int. J. Cancer. 2006 ; 119: 414-422
12. Hyafil F., Vergely C., Du Vignaud P., Grand-Perret T.. In Vitro and In Vivo Reversal of Multidrug Resistance by GF120918, an Acridonecarboxamide Derivative. Cancer Res. 1993 ; 53: 4595-4602
13. Gerrard G., Payne E., Baker R. J., Jones D. T., Potter M., Prentice H. G., Ethell M., McCullough H., Burgess M., Mehta A. B., et al. Clinical Effects and P-glycoprotein Inhibition in Patients with Acute Myeloid Leukemia Treated with Zosuquidar Trihydrochloride, Daunorubicin and Cytarabine. Haematologica. 2004 ; 89: 782-790
14. Saeki T., Nomizu T., Toi M., Ito Y., Noguchi S., Kobayashi T., Asaga T., Minami H., Yamamoto N., Aogi K., et al. Dofequidar Fumarate (MS-209) in Combination with Cyclophosphamide, Doxorubicin, and Fluorouracil for Patients with Advanced or Recurrent Breast Cancer. J. Clin. Oncol. 2007 ; 25: 411-417
15. van Zuylen L., Sparreboom A., van der Gaast A., Nooter K., Eskens F. A. L. M., Brouwer E., Bol C. J., de Vries R., Palmer P. A., Verweij J.. Disposition of Docetaxel in the Presence of P-glycoprotein Inhibition by Intravenous Administration of R101933. Eur. J. Cancer. 2002 ; 38: 1090-1099
16. Guns E. S., Denyssevych T., Dixon R., Bally M. B., Mayer L.. Drug Interaction Studies between Paclitaxel (Taxol) and OC144-093-A New Modulator of MDR in Cancer Chemotherapy. Eur. J. Drug Metab. Pharmacokinet. 2002 ; 27: 119-126
17. Allen J. D., Van Loevezijn A., Lakhai J. M., Van der Valk M., Van Tellingen O., Reid G., Schellens J. H., Koomen G. J., Schinkel A. H.. Potent and Specific Inhibition of the Breast Cancer Resistance Protein Multidrug Transporter In Vitro and in Mouse Intestine by a Novel Analogue of Fumitremorgin C. Mol. Cancer Ther. 2002 ; 1: 417-425
18. Rabindran S. K., Ross D. D., Doyle L. A., Yang W., Greenberger L. M.. Fumitremorgin C Reverses Multidrug Resistance in Cells Transfected with the Breast Cancer Resistance Protein. Cancer Res. 2000 ; 60: 47-50
19. Abe T., Koike K., Ohga T., Kubo T., Wada M., Kohno K., Mori T., Hidaka K., Kuwano M.. Chemosensitisation of Spontaneous Multidrug Resistance by a 1,4-dihydropyridine Analogue and Verapamil in Human Glioma Cell Lines Overexpressing MRP or MDR1. Br. J. Cancer. 1995 ; 72: 418-423
20. Robey R. W., Polgar O., Deeken J., To K. W., Bates S. E.. ABCG2: Determining Its Relevance in Clinical Drug Resistance. Cancer Metastasis Rev. 2007 ; 26: 39-57
21. Garimella T. S., Ross D. D., Eiseman J. L., Mondick J. T., Joseph E., Nakanishi T., Bates S. E., Bauer K. S.. Plasma Pharmacokinetics and Tissue Distribution of the Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitor Fumitremorgin C in SCID Mice Bearing T8 Tumors. Cancer Chemother. Pharmacol. 2005 ; 55: 101-109
22. Robey R. W., Medina-Perez W. Y., Nishiyama K., Lahusen T., Miyake K., Litman T., Senderowicz A. M., Ross D. D., Bates S. E.. Overexpression of the ATP-Binding Cassette Half-Transporter, ABCG2 (MXR/BCRP/ABCP1), in Flavopiridol-Resistant Human Breast Cancer Cells. Clin. Cancer Res. 2001 ; 7: 145-152
23. Thiessen B., Stewart C., Tsao M., Kamel-Reid S., Schaiquevich P., Mason W., Easaw J., Belanger K., Forsyth P.. A Phase I/II Trial of GW572016 (Lapatinib) in Recurrent Glioblastoma Multiforme: Clinical Outcomes, Pharmacokinetics and Molecular Correlation. Cancer Chemother. Pharmacol. 2010 ; 65: 353-361
24. Mistry P., Plumb J., Eccles S., Watson S., Dale I., Ryder H., Box G., Charlton P., Templeton D., Bevan P. B.. In Vivo Efficacy of XR9051, a Potent Modulator of P-glycoprotein Mediated Multidrug Resistance. Br. J. Cancer. 1999 ; 79: 1672-1678
25. Vellenga E., Tuyt L., Wierenga B.-J., Muller M., Dokter W.. Interleukin-6 Production by Activated Human Monocytic Cells Is Enhanced by MK-571, a Specific Inhibitor of the Multi-drug Resistance Protein-1. Br. J. Pharmacol. 1999 ; 127: 441-448
26. Burkhart C. A., Watt F., Murray J., Pajic M., Prokvolit A., Xue C., Flemming C., Smith J., Purmal A., Isachenko N., et al. Small-Molecule Multidrug Resistance-Associated Protein 1 Inhibitor Reversan Increases the Therapeutic Index of Chemotherapy in Mouse Models of Neuroblastoma. Cancer Res. 2009 ; 69: 6573-6580
27. Estes D. A., Lovato D. M., Khawaja H. M., Winter S. S., Larson R. S.. Genetic Alterations Determine Chemotherapy Resistance in Childhood T-ALL: Modelling in Stage-Specific Cell Lines and Correlation with Diagnostic Patient Samples. Br. J. Haematol. 2007 ; 139: 20-30
28. Kuckuck F. W., Edwards B. S., Sklar L. A.. High Throughput Flow Cytometry. Cytometry. 2001 ; 44: 83-90
29. Ramirez S., Aiken C. T., Andrzejewski B., Sklar L. A., Edwards B. S.. High-Throughput Flow Cytometry: Validation in Microvolume Bioassays. Cytometry. 2003 ; 53: 55-65
30. Ivnitski-Steele I., Larson R. S., Lovato D. M., Khawaja H. M., Winter S. S., Oprea T. I., Sklar L. A., Edwards B. S.. High-Throughput Flow Cytometry to Detect Selective Inhibitors of ABCB1, ABCC1, and ABCG2 Transporters. Assay Drug Dev. Technol. 2008 ; 6: 263-276
31. Winter S. S., Lovato D. M., Khawaja H. M., Edwards B. S., Steele I. D., Young S. M., Oprea T. I., Sklar L. A., Larson R. S.. High-Throughput Screening for Daunorubicin-Mediated Drug Resistance Identifies Mometasone Furoate as a Novel ABCB1-Reversal Agent. J. Biomol. Screen. 2008 ; 13: 185-193
32. National Center for Biotechnology Information. PubChem BioAssay Database; AID=1818, Source=University of New Mexico Center for Molecular Discovery. http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=1818&loc=ea-ras
33. Robins M. J., Uznanski B.. Nucleic acid related compounds. 33. Conversions of adenosine and guanosine to 2,6-dichloro, 2-amino-6-chloro, and derived purine nucleosides. Can. J. Chem. 1981 ; 59: 2601-2607